The largest database of trusted experimental protocols

23 protocols using ifn α

1

Dose-Dependent Cytokine Profiling for Transcriptomic Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
Data represented in Figures 5A–5L: Cytokines were added for 12 h overnight at increasing doses (0, 0.1, 0.5, 1, 2, 5, 10 ng/mL) of IL-4 (human: Biolegend 574002), IL-17A (human: Biolegend 570502), IFNγ (human: Biolegend 570202; mouse: Peprotech 315-05), IFNα (human: Biolegend 592702; mouse: Biolegend 752802), or IFNβ (mouse: R&D Systems 8234-MB-010). Each condition was run as a biological triplicate. Data represented in Figure S3C-K: cytokines were added for 12 h overnight at increasing doses (0, 0.1, 0.5, 1, 5, 10 ng/mL) of human IL-4 (Biolegend 574004), IL-13 (Biolegend 571104), IFNα (Biolegend 592704), IFNγ (Biolegend 570204), IL-17A (Biolegend 570504), or IL-1β (Biolegend 579404) (each condition run as a biological quadruplicate). All populations were lysed in 50 μL lysis buffer (RLT + 1% BME, QIAGEN and Sigma, respectively) and snap frozen on dry ice. Bulk RNA-seq was performed as described previously and summarized above (Ordovas-Montanes et al., 2018 (link)). Populations were sequenced to an average ± SEM read depth of 3.95 ± 0.11 million reads per sample, with an average ± SEM alignment percentage to either hg19 or mm10 reference transcriptomes of 71 ± 0.3%. All samples met quality thresholds regarding genomic and transcriptomic alignment.
+ Open protocol
+ Expand
2

Zbtb20 Expression in Cultured Splenic B Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
AutoMACS-isolated splenic B cells from naïve mice were cultured in the presence of IL-1β (5 ng/mL; BioLegend), IL-6 (40 ng/mL; BioLegend) IL-9 (12.5 ng/mL; BioLegend), IL-12 (5 ng/mL; R&D Systems), IL-33 (40 ng/mL; Peprotech), IFN-α (1000 U/mL; BioLegend), IFN-β (500 U/mL; BioLegend), or IFN-γ (200 ng/mL; BioLegend) with lipopolysaccharide (LPS; 10 ng/mL) for 24 h at 37 °C. Cells were subjected to Zbtb20 intracellular staining or lysed for qRT-PCR assays.
+ Open protocol
+ Expand
3

Immortalized Mouse Macrophage Reporter Cell Line

Check if the same lab product or an alternative is used in the 5 most similar protocols
Immortalized bone marrow-derived mouse macrophage (iBMDM) cells (37 (link)) were cultured in Dulbecco’s Modified Eagle Medium (DMEM) with L-glutamine (Sigma-Aldrich), supplemented with 10% (v/v) of heat-inactivated Foetal Bovine Serum (Life Technologies Ltd) and 1% (v/v) of Penicillin-Streptomycin (Sigma-Aldrich) solution. Cells were cultured between passages 6-30 in sterile NuncTM 10 cm cell culture petri dishes (ThermoFisher Scientific) till 80-90% confluent. Lentiviral transduction (38 (link)) was used to develop reporter iBMDM line expressing murine STAT1 coding sequence C-terminally fused with the red fluorescent protein (STAT1-tagRFP) and murine STAT6 coding sequence N-terminally fused with yellow fluorescent protein (Venus-STAT6). Additionally, cells expressed histone H2B protein fused with cyan fluorescent protein (AmCyan-H2B). iBMDMs were sequentially transduced and triple positive cells were identified using fluorescence single cell sorter (BD Influx) to derive a clonal reporter line. Cells were stimulated with recombinant mouse IFN-γ (575306, Biolegend), IL-4 (574306, Biolegend), IFN-α (752802, Biolegend) and IFN-β1 (581302, Biolegend).
+ Open protocol
+ Expand
4

In Vitro NHEK Culture and Stimulation

Check if the same lab product or an alternative is used in the 5 most similar protocols
Normal human epidermal keratinocytes (NHEKs) were purchased from Thermo Fisher Scientific and maintained for up to 6 passages in T-75 flasks or used earlier. Cells were grown in serum-free EpiLife cell culture medium with EpiLife Defined Growth Supplement containing 0.06 mM Ca2+ (Gibco, Waltham, MA) or Keratinocyte serum-free-media (KSFM) with supplements provided by manufacturer (Gibco) and additional 0.06mM Ca2+. NHEKs were grown to approximately 75-80% confluence. For experiments, cells between passage 3-6 were plated at approximately 200,000 cells/well in 6-well plates and 75,000 cells/chamber in 2-chamber slides, respectively (LabTek, Bloomington, IN). For some experiments, IL-27 was used at a concentration of 100 ng/mL; IFN-α was used at a concentration of 50 U/mL (BioLegend). The cells were collected for quantitative RT-PCR or immunofluorescence at various time points.
+ Open protocol
+ Expand
5

Cytokine-Induced STAT Phosphorylation Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
Forty-eight hours after transduction, cells were first reseeded in IL-2–free media for 4 h, then cultured in RPMI medium with 10% FBS and anti–CD8-biotin Ab (53–6.7; eBioscience) in the presence or absence of rIL-2 (50 U/ml) for 10 min to induce STAT5 phosphorylation. For STAT1 and STAT3 phosphorylation, cells were cultured in the presence or absence of IFN-α (5000 U/ml; 30 min; BioLegend) or IL-21 (200 ng/ml; 30 min; BioLegend), respectively, and anti–CD8-biotin was added for the last 10 min. Cells were then fixed in 2% paraformaldehyde (5 min) and fixation reagent (15 min) (FIX & PERM Cell Permeabilization Kit; Thermo Fisher Scientific) and made permeable with ice-cold methanol (15 min) and permeabilization medium (FIX & PERM Cell Permeabilization Kit; Thermo Fisher Scientific), then stained with anti-GFP Ab (Thermo Fisher Scientific), anti–p-STAT1-PE (A15158B), anti–p-STAT3-AF647 (13A3–1; all from BioLegend), anti–p-STAT5 allophycocyanin (SRBCZX), streptavidin-PE (all from eBioscience), and streptavidin-allophycocyanin (Invitrogen). Cells were analyzed with a CytoFLEX S (Beckman Coulter) Flow Cytometer.
+ Open protocol
+ Expand
6

Cytokine-Induced Keratinocyte Response

Check if the same lab product or an alternative is used in the 5 most similar protocols
Medium was removed, and new medium containing cytokines was used to stimulate keratinocytes for a variety of time points. Unless stated otherwise, IL-6, IL-23, IL-27, IL-35 (all from BioLegend), and IL-12 (Tonbo) were added to 1 to 2 ml of medium at a concentration of 100 ng/ml; IFN-α (BioLegend) or IFN-γ (PeproTech) was added to 1 to 2 ml of media at a concentration of 50 U/ml. For the cytotoxicity study, cells were suspended in CellTiter 96 AQueous One Solution Reagent and then incubated at 37°C for 1 to 4 hours in a humidified, 5% CO2 atmosphere. Absorbance was read at 490 nm using a 24-well plate reader.
+ Open protocol
+ Expand
7

Lupus Murine Model Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
MRL/lpr-Igkm/h mice have been previously described (8 (link), 9 (link)). Male and female mice 6-16 weeks of age were used in experiments. For some analyses, groups of 6-7 week old MRL/lpr-Igkm/h mice were first injected i.p. with 200 μg of CpG ODN 1826 (IDT) twice a week for four weeks, or with 0.9 μg or 9.0 μg of IFNα (BioLegend) every other day for one week. Control mice were injected with equal volume of PBS. Mice were housed in Specific Pathogen Free conditions at the University of Colorado Anschutz Medical Campus (UCD-AMC). All animal procedures were approved by the UCD-AMC Institutional Animal Care and Use Committee and carried out in accordance with approved guidelines.
+ Open protocol
+ Expand
8

Cytokine-Induced STAT Phosphorylation Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
Forty-eight hours after transduction, cells were first reseeded in IL-2–free media for 4 h, then cultured in RPMI medium with 10% FBS and anti–CD8-biotin Ab (53–6.7; eBioscience) in the presence or absence of rIL-2 (50 U/ml) for 10 min to induce STAT5 phosphorylation. For STAT1 and STAT3 phosphorylation, cells were cultured in the presence or absence of IFN-α (5000 U/ml; 30 min; BioLegend) or IL-21 (200 ng/ml; 30 min; BioLegend), respectively, and anti–CD8-biotin was added for the last 10 min. Cells were then fixed in 2% paraformaldehyde (5 min) and fixation reagent (15 min) (FIX & PERM Cell Permeabilization Kit; Thermo Fisher Scientific) and made permeable with ice-cold methanol (15 min) and permeabilization medium (FIX & PERM Cell Permeabilization Kit; Thermo Fisher Scientific), then stained with anti-GFP Ab (Thermo Fisher Scientific), anti–p-STAT1-PE (A15158B), anti–p-STAT3-AF647 (13A3–1; all from BioLegend), anti–p-STAT5 allophycocyanin (SRBCZX), streptavidin-PE (all from eBioscience), and streptavidin-allophycocyanin (Invitrogen). Cells were analyzed with a CytoFLEX S (Beckman Coulter) Flow Cytometer.
+ Open protocol
+ Expand
9

Generating GM-BMDMs and CD122+ Macrophages

Check if the same lab product or an alternative is used in the 5 most similar protocols
Single-cell suspensions of BM were prepared as above. Adherent cells were removed by incubating bulk bone marrow cells on tissue culture-treated plates for at least 2 hours in complete DMEM (cDMEM, 10% FBS, 1% Pencillin/Streptomycin/Glutamine). Non-adherent cells were then collected, counted, and plated at 5x105 cells/mL in cDMEM containing 10% L929 cell-conditioned medium (LCM, made in our laboratory) for 5-7 days. GM-BMDMs were generated by culturing non-adherent BM cells in cDMEM supplemented with 50ng/mL GM-CSF (Peprotech). CD122+BMDMs were generated by adding 1ng/mL IFNα (Biolegend) to the medium on day 5 of culture. When testing ability of IFNγ (Peprotech) to derive CD122+Macs, doses indicated were added on day 5 of culture. Anti-IFNAR and anti-IFNGR (both BioXcell) were both used at 10μg/mL in culture.
+ Open protocol
+ Expand
10

Stimulation and Activation of BMDMs

Check if the same lab product or an alternative is used in the 5 most similar protocols
For TLR4 stimulation, BMDMs were stimulated with different doses of LPS (Invivogen) for 30 min, washed, and further incubated for 5.5 h before harvest. To evaluate BMDMs' response to poly(I:C) via endosomal/lysosomal pathway or cytosolic PPR sensing pathway, BMDMs were either incubated with 50 μg/ml of naked poly(I:C) or transfected with 2 μg/ml of Lipofectamine 2000 (Invitrogen) packaged poly(I:C) (Invivogen), respectively. For cytokine stimulation, BMDMs were treated with different doses of IFN‐α (BioLegend), IFN‐β (R&D systems), and IFN‐γ (BioLegend) for various length of time as indicated in the figures.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!